Clinical Trial Update: Compassionate Use (CU) of REGN5458 for Patients With Relapsed or Refractory Multiple Myeloma (MM)

View source ↗

Summary

Regeneron reports compassionate-use access for REGN5458 in relapsed or refractory multiple myeloma, and the trial page notes that REGN5458 has been approved for…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• REGN5458

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Multiple Myeloma | Status: APPROVED_FOR_MARKETING